Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.
Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.
复制标题
长春地辛：儿童恶性肿瘤的 II 期研究——针对 B 组癌症和白血病的报告。
DOI：
10.1002/mpo.2950100107
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
Ohnuma,T
中科院分区：
文献类型：
--
作者：
Ettinger,LJ;Brecher,M;Coleman,M;Smithson,WA;Patterson,R;Russell,EC;Necheles,T;Jones,B;Ohnuma,T
Vindesine, a semisynthetic derivative of vinblastine sulfate, was tested for anti‐tumor activity and clinical toxicity in 36 children. The drug was administered to the initial 13 patients entered into the study a 2 mg/m2/day for five days by IV bolus. Because of severe neurotoxicity and life‐threatening gastrointestinal toxicity, the regimen in 23 patients was modified to 4 mg/m2IV infusion over four hours, weekly. This latter regimen was well tolerated, with acceptable gastrointestinal, hematological, and neurotoxicity. One child with acute lymphocytic leukemia resistant to vincristine had a transient Ml remission bone marrow. Improvement or stable disease was noted in one patient each with Ewing's sarcoma, neuroblastoma, and Hodgkin's disease.
